Peptide-Based Probe Targeting Angiotensin Type-1 Receptor Identifies Pancreatic Ductal Adenocarcinoma Using Multispectral Optoacoustic Tomography
Chemical & Biomedical Imaging · 23.03.2026 · 4 (3) · 410-421
DOI: 10.1021/cbmi.5c00128 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical & Biomedical Imaging, online erschienen am 25.11.2025. Verfasst von Rohit Singh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Stephenson Cancer Center, Department of Surgery, University of Oklahoma, Oklahoma City, Oklahoma 73104, United States. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Cancer Institute.
Abstract (Originalsprache)
Purpose
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal and aggressive malignancies with limited treatment options. Curative surgical resection of the primary pancreatic mass is frequently limited by residual microscopic tumor foci, leading to a high recurrence rate in patients. To improve surgical outcomes, visualizing remaining tumor foci with fluorescent probes is crucial to achieve complete (R0) resection.
Methods
A peptide-based imaging probe targeting the angiotensin type-1 receptor was engineered with either 555 or 750 nm reporter dyes. Immunofluorescence and NIR imaging analyses were performed to assess receptor interactions and binding probes in AT1R-positive PDAC cells and low (HT-29) control cells. Probe uptake in the complex PDAC microenvironment of orthotopic mouse models (S2VP10 and S2O13) was evaluated using multispectral optoacoustic tomography (MSOT). Ex vivo biodistribution was confirmed, and toxicity was measured in the treated mice.
Results
PDAC cells demonstrated membranous expression of angiotensin type-1 receptor, which was absent in the HT-29 control cells. An engineered NIR probe, Angio1-750, was synthesized and characterized. Docking analysis of the engineered peptide with the targeted receptor demonstrated binding. PDAC cells treated with Angio1-750 probe showed a higher signal than the HT-29 cells. The PDAC tumor had a detectable signal in MSOT (S2VP10 61 ± 7.64 a.u. at 3 h and 43.18 ± 4.51 a.u. at 24 h, P < 0.0004; S2O13 25.30 ± 1.53 a.u. at 3 h and 17.33 ± 0.58 a.u. at 24 h, P = 0.05). Biodistribution analysis revealed tumor uptake and confirmed the renal excretion of the probe.
Conclusions
The data suggest successful tumor uptake of the Angio1-750 probe and detection using MSOT in PDAC xenografts.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Stephenson Cancer Center, Department of Surgery, University of Oklahoma, Oklahoma City, Oklahoma 73104, United States.
- Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama 35294, United States.
- Department of Medicine, University of Oklahoma, Oklahoma City, Oklahoma 73104, United States.
ORCID-Profile: Lacey R McNally
Förderung
- National Cancer Institute
Zitieren
APA
Singh, R., Agarwal, H., Bynum, R. C., Grizzle, W. E., Jain, A., Edil, B. H., Ulahannan, S., Li, M., & McNally, L. R. (2026). Peptide-Based Probe Targeting Angiotensin Type-1 Receptor Identifies Pancreatic Ductal Adenocarcinoma Using Multispectral Optoacoustic Tomography. Chemical & Biomedical Imaging, 4(3), 410-421. https://doi.org/10.1021/cbmi.5c00128
Vancouver
Singh R, Agarwal H, Bynum RC, Grizzle WE, Jain A, Edil BH, et al. Peptide-Based Probe Targeting Angiotensin Type-1 Receptor Identifies Pancreatic Ductal Adenocarcinoma Using Multispectral Optoacoustic Tomography. Chemical & Biomedical Imaging. 2026;4(3):410-421. doi:10.1021/cbmi.5c00128
BibTeX
@article{Singh2026,
author = {Singh, Rohit and Agarwal, Happy and Bynum, Ryan C and Grizzle, William E and Jain, Ajay and Edil, Barish H and Ulahannan, Susanna and Li, Min and McNally, Lacey R},
title = {Peptide-Based Probe Targeting Angiotensin Type-1 Receptor Identifies Pancreatic Ductal Adenocarcinoma Using Multispectral Optoacoustic Tomography},
journal = {Chemical & Biomedical Imaging},
year = {2026},
volume = {4},
number = {3},
pages = {410--421},
doi = {10.1021/cbmi.5c00128}
}
EUVIMED